@BLLBscamtracker@Stocks_n_Stones I will say I can see where you're coming from on the "looks like a scam", but we actually had a horse treated with Isopet (basically Radiogel) in New Hampshire and it's legit. Worked as advertised. They now have a few official employees beyond advisory board and people helping.
@QueTraders@RadioGel We had a horse treated with Isopet which is basically the same thing as Radiogel. I can confirm it worked as described in front of my own eyes. This isn't a idea on paper, it actually works.
@cdntradegrljenn I think so but would have to double check. They're submitting for IDE within the next 90 days. India trials are going very well. Just figured you'd like this one pre-IDE even if there'sa small offering still. Hope the weather is good up your way. Spring time baby!
@suebutcher@ClearUTL@IsoPetForCancer No. They use y90 and the radiation travels such a short distance, there's no concern for isolation unlike other ones. This allows them to attack the cancer cells and not healthy ones. Also, y90 has a half life of roughly 2.5 days so by day 10, there's basically no radiation left.
@BradWeeks0331 I was going to ask you the other day if treating margins was going to still be a thing. This is very exciting! Hope to see this use in humans in the near future. I also saw Isopet's magic on our friend's horse. I almost wouldn't believe it if I didn't see the before and after.
@cdntradegrljenn It's like anything else in the world. The majority of people are good people, but thanks to the media in general, you only hear about the loud small minority of the extreme.
My only complaint about Canada is they have better gold panning than we do here in Maine, USA!
@cdntradegrljenn@Jonatha18054953 Jen, they just successfully treated 5 people for thyroid cancer in India with no complications. Just was approved to treat 30 more people ANYWHERE in the body.
Their Reg A is usually small to fund Isopet or Radiogel activities. Very conservative, responsible and negligible.
@JohnZidar This is completely wrong. The FDA and the company both agreed that 30 days wasn't enough time to review this very complex submission and agreed to basically extend the review.